Top

Published in:

01-04-2016 | Other

Endoluminal therapies for Barrett’s esophagus

Authors: Carmen L. Mueller, Lorenzo E. Ferri

Published in: Obesity Surgery | Issue 4/2016

Abstract

This paper reviews currently available endoluminal therapies for Barrett’s esophagus, which may be integrated into the care of obese and bariatric surgery patients.

Spechler SJ, Souza RF. Barrett’s esophagus. N Engl J Med. 2014;371(9):836–45. doi:10.1056/NEJMra1314704.CrossRefPubMed

Schigt A, Coblijn U, Lagarde S, Kuiken K, Scholten P, van Wagensveld B van. Is esophagogastroduodenoscopy before Roux-en-Y gastric bypass or sleeve gastrectomy mandatory? Surg Obes Relat Dis. 2014;10(3):411–418. doi:10.1016/j.soard.2014.01.015.

Zeni T, Frantzides C, Mahr C, et al. Value of preoperative upper endoscopy in patients undergoing laparoscopic gastric bypass. Obes Surg. 2006;16:142–6. doi:10.1381/096089206775565177.CrossRefPubMed

El-Serag HB. Obesity and disease of the esophagus and colon. Gastroenterol Clin North Am. 2005;34(1):63–82. doi:10.1016/j.gtc.2004.12.006.CrossRefPubMed

Kramer JR, Fischbach LA, Richardson P, et al. Waist-to-Hip ratio, but not body mass index, is associated with an increased risk of Barrett’s esophagus in white men. Clin Gastroenterol Hepatol. 2013;11(4):373–81. doi:10.1016/j.cgh.2012.11.028. e1.CrossRefPubMedPubMedCentral

Chandar A, Iyer P. Role of obesity in the pathogenesis and progression of Barrett’s esophagus. Gastroenterol Clin N Am. 2015;44:249–64.CrossRef

Braghetto I, Csendes A. Prevalence of Barrett’s esophagus in bariatric patients undergoing sleeve gastrectomy. Obes Surg. 2015:epub April 9, 2015. doi:10.1007/s11695-015-1574-1.

Csendes A, Burgos A, Smok G, Burdiles P, Henriquez A. Effect of gastric bypass on Barrett’s esophagus and intestinal metaplasia of the cardia in patients with morbid obesity. J Gastrointest Surg. 2006;10(2):259–64. doi:10.1016/j.gassur.2005.06.006.CrossRefPubMed

Hvid-Jensen F, Pedersen L, Drewes A, Sørensen H, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.CrossRefPubMed

10.

Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140(3):1084–91. doi:10.1053/j.gastro.2011.01.030.CrossRefPubMed

11.

Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(10):1245–55. doi:10.1016/j.cgh.2013.03.039.CrossRefPubMed

12.

Phoa KN, van Vilsteren FGI, Weusten BL AM, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. Jama. 2014;311(12):1209–17. doi:10.1001/jama.2014.2511.CrossRefPubMed

13.

Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141(2):460–8. doi:10.1053/j.gastro.2011.04.061.CrossRefPubMedPubMedCentral

14.

Shaheen N, Sharma P, Overholt B, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360(22):2277–88.CrossRefPubMed

15.

Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol. 2015;110(5):662–82. doi:10.1038/ajg.2015.55.CrossRefPubMed

16.

Mino-Kenudson M, Hull MJ, Brown I, et al. EMR for Barrett’s esophagus–related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc. 2007;66(4):660–6. doi:10.1016/j.gie.2007.02.063.CrossRefPubMed

17.

Wani S, Abrams J, Edmundowicz SA, et al. Endoscopic mucosal resection results in change of histologic diagnosis in Barrett’s esophagus patients with visible and flat neoplasia: a multicenter cohort study. Dig Dis Sci. 2013;58(6):1703–9. doi:10.1007/s10620-013-2689-7.CrossRefPubMedPubMedCentral

18.

Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology. 2009;137(3):815–23. doi:10.1053/j.gastro.2009.05.059.CrossRefPubMed

19.

Bulsiewicz WJ, Dellon ES, Rogers AJ, et al. The impact of endoscopic ultrasound findings on clinical decision making in Barrett’s esophagus with high-grade dysplasia or early esophageal adenocarcinoma. Dis Esophagus. 2014;27(5):409–17. doi:10.1111/j.1442-2050.2012.01408.x.CrossRefPubMedPubMedCentral

20.

Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76(6):1087–94. doi:10.1016/j.gie.2012.08.004.CrossRefPubMed

21.

Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219–25.CrossRefPubMed

22.

Lee L, Ronellenfitsch U, Hofstetter WL, et al. Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system. J Am Coll Surg. 2013;217(2):191–9. doi:10.1016/j.jamcollsurg.2013.03.015.CrossRefPubMed

23.

Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62(4):488–98. doi:10.1016/j.gie.2005.06.047.CrossRefPubMed

24.

Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc. 2007;66(3):460–8. doi:10.1016/j.gie.2006.12.037.CrossRefPubMed

25.

Dulai GS, Jensen DM, Cortina G, Fontana L, Ippoliti A. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett’s esophagus. Gastrointest Endosc. 2005;61(2):232–40. doi:10.1016/S0016-5107(04)02576-3.CrossRefPubMed

26.

Shaheen NJ, Greenwald B, Peery AF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 2010;71(4):680–5. doi:10.1016/j.gie.2010.01.018.Safety.CrossRefPubMedPubMedCentral

27.

Kantsevoy SV, Adler DG, Conway JD, et al. Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc. 2008;68(1):11–8. doi:10.1016/j.gie.2008.01.037.CrossRefPubMed

28.

Guo H-M, Zhang X-Q, Chen M, Huang S-L, Zou X-P. Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer. World J Gastroenterol. 2014;20(18):5540–7. doi:10.3748/wjg.v20.i18.5540.CrossRefPubMedPubMedCentral

29.

Chadwick G, Groene O, Markar SR, Hoare J, Cromwell D, Hanna GB. Systematic review comparing radiofrequency ablation and complete endoscopic resection in treating dysplastic Barrett’s esophagus: a critical assessment of histologic outcomes and adverse events. Gastrointest Endosc. 2014;79(5):718–731.e3. doi:10.1016/j.gie.2013.11.030.

30.

Gerke H, Siddiqui J, Nasr I, Van Handel DM, Jensen CS. Efficacy and safety of EMR to completely remove Barrett’s esophagus: experience in 41 patients. Gastrointest Endosc. 2011;74(4):761–71. doi:10.1016/j.gie.2011.06.009.CrossRefPubMed

31.

Chennat J, Konda VJ, Ross AS, et al. Complete Barrett’s eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma—an american single-center experience. Am J Gastroenterol. 2009;104(11):2684–92. doi:10.1038/ajg.2009.465.CrossRefPubMed

32.

Kagemoto K, Oka S, Tanaka S, et al. Clinical outcomes of endoscopic submucosal dissection for superficial Barrett’s adenocarcinoma. Gastrointest Endosc. 2014;80(2):239–45. doi:10.1016/j.gie.2014.01.022.CrossRefPubMed

33.

Higuchi K, Tanabe S, Azuma M, et al. A phase II study of endoscopic submucosal dissection for superficial esophageal neoplasms (KDOG 0901). Gastrointest Endosc. 2013;78(5):704–10. doi:10.1016/j.gie.2013.04.182.CrossRefPubMed

34.

Korst RJ, Santana-Joseph S, Rutledge JR, et al. Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett’s esophagus. J Thorac Cardiovasc Surg. 2013;145(6):1529–34. doi:10.1016/j.jtcvs.2012.11.016.CrossRefPubMed

Title: Endoluminal therapies for Barrett’s esophagus
Authors: Carmen L. Mueller
Lorenzo E. Ferri
Publication date: 01-04-2016
Publisher: Springer US
Published in: Obesity Surgery / Issue 4/2016
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-015-2010-2

At a glance: The STEP trials

Springer Medicine

Endoluminal therapies for Barrett’s esophagus

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Preoperative Nutrition and Postoperative Discomfort in an ERAS Setting: A Randomized Study in Gastric Bypass Surgery

Technique of Hill’s Gastropexy Combined with Sleeve Gastrectomy for Patients with Morbid Obesity and Gastroesophageal Reflux Disease or Hiatal Hernia

Letter: Primary Hyperparathyroidism after Roux-en-Y gastric Bypass

Malnutrition in Bariatric Surgery Candidates: Multiple Micronutrient Deficiencies Prior to Surgery

Is Bariatric Surgery Effective in Reducing Comorbidities and Drug Costs? Reply to Letter to the Editor

Postoperative Follow-up After Bariatric Surgery: Effect on Weight Loss